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Abstract
Background There is a marked need for improved animal models of nonalcoholic steatohepatitis (NASH) to facilitate the 
development of more efficacious drug therapies for the disease.
Methods Here, we investigated the development of fibrotic NASH in male Wistar rats fed a choline-deficient l-amino acid-
defined (CDAA) diet with or without cholesterol supplementation for subsequent assessment of drug treatment efficacy 
in NASH biopsy-confirmed rats. The metabolic profile and liver histopathology were evaluated after 4, 8, and 12 weeks 
of dieting. Subsequently, rats with biopsy-confirmed NASH were selected for pharmacological intervention with vehicle, 
elafibranor (30 mg/kg/day) or obeticholic acid (OCA, 30 mg/kg/day) for 5 weeks.
Results The CDAA diet led to marked hepatomegaly and fibrosis already after 4 weeks of feeding, with further progression 
of collagen deposition and fibrogenesis-associated gene expression during the 12-week feeding period. Cholesterol supple-
mentation enhanced the stimulatory effect of CDAA on gene transcripts associated with fibrogenesis without significantly 
increasing collagen deposition. Pharmacological intervention with elafibranor, but not OCA, significantly reduced stea-
tohepatitis scores, and fibrosis-associated gene expression, however, was unable to prevent progression in fibrosis scores.
Conclusion CDAA-fed rats develop early-onset progressive NASH, which offers the opportunity to probe anti-NASH com-
pounds with potential disease-modifying properties.
Keywords NASH · CDAA · Cholesterol · Elafibranor · OCA · Fibrosis
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most com-
mon liver disease influencing approximately 25% of the 
general population of the Western countries [1, 2]. NAFLD 
ranges from benign, steatosis to its most aggressive mani-
festation, nonalcoholic steatohepatitis (NASH), which is 
characterized by steatosis, inflammation, and hepatocyte 
degeneration (ballooning) [3]. Patients with NASH are at 
increased risk of developing liver fibrosis which is the main 
prognostic factor for cirrhosis, primary liver cancer, and 
end-stage liver disease [4, 5]. With the increasing NASH 
burden, it is therefore projected that advanced fibrotic 
NASH will be the leading indication for liver transplanta-
tion in developing countries by 2020 [6]. Although consid-
erable progress has been made in the understanding of the 
cellular and molecular mechanisms in NASH, no evidence-
based drug treatments approved for NASH management 
exist. NASH is therefore classified as a medical condition 
with high unmet therapeutic need. Several drug treatment 
concepts are in various stages of clinical development for 
NASH [7, 8].
The primary driver of NASH is overnutrition and obesity. 
Several diet-induced obese (DIO) models of NASH have 
been developed in an attempt to mimic the etiology of the 
disease [9]. Animals fed a diet high in fat and carbohydrates 
develop adiposity, insulin resistance, dyslipidemia, and fatty 
liver. Depending on the macronutrient composition, the DIO 
models may also exhibit features of liver inflammation and, 
to some degree, hepatocyte ballooning [10–16]. A major 
challenge with the high-fat/carbohydrate dieting paradigms 
is that very long dieting periods (typically > 20 weeks) 
are required for the steatohepatitis condition to progress 
to hepatic fibrosis. Furthermore, the DIO models do not 
consistently exhibit histopathological features of advanced 
fibrotic (pre-cirrhotic) NASH making these animal models 
most applicable for probing drug effects on less severe stages 
of the disease [9, 17, 18]. The insufficient fibrotic response 
to hypercaloric diets has led to the development of nutrient-
deficient dietary concepts that promote faster onset of NASH 
and severe fibrosis reminiscent of severe fibrotic NASH in 
humans [9]. Nutrient-deficient dietary models are either low 
or devoid of methionine and/or choline. Choline-deficient 
diets with low methionine levels can be made even less lipo-
trope by replacing nutrient proteins with l-amino acids, i.e., 
choline-deficient amino acid-defined (CDAA) diet, which 
further impedes hepatic lipid clearance that enhances hepa-
tomegaly, steatosis, and lipotoxic hepatocyte damage. In rats 
and mice, CDAA diet regimens promote severe fibrosis with 
the development of frank cirrhosis after extended dieting 
periods [19–22]. In contrast to the pronounced weight loss 
attained by methionine–choline-deficient (MCD) dieting 
regimens, CDAA diets are weight neutral [20, 23], which 
makes the CDAA model attractive for also assessing effects 
on gross metabolic parameters of potential anti-NASH com-
pounds. Although the CDAA model has been extensively 
characterized in the context of hepatopathology, relatively 
few pharmacological studies have so far been reported in 
rodent CDAA models of NASH [19, 22, 24–27], and there 
is a marked lack of knowledge on the responsiveness of the 
CDAA model to drugs that are in current clinical develop-
ment for NASH [9].
Hepatic cholesterol homeostasis is dysregulated in 
NAFLD, and there is an increasing appreciation that the 
lipotoxic properties of elevated free cholesterol can contrib-
ute to the development and progression of NASH by stimu-
lation of detrimental immune cell responses with resulting 
hepatocyte necroinflammation and enhanced fibrogenesis 
[28, 29]. We therefore investigated whether cholesterol sup-
plementation could enhance the hepatotoxic properties of 
CDAA dieting in rats, as compared to CDAA dieting alone. 
In addition, we characterized the effects of obeticholic 
acid (OCA) and elafibranor in this novel cholesterol-sup-
plemented CDAA rat model of NASH. Both compounds 
are in late-stage clinical development for NASH [30, 31]. 
OCA is a first-in-class semisynthetic bile acid exerting its 
effect by binding to the nuclear farnesoid X receptor (FXR), 
thereby activating several regulators in bile acid synthesis 
and transport, hepatic lipid, and carbohydrate metabolism as 
well as immune function [32–35]. OCA attenuates hepatic 
inflammation and reduces low-grade hepatocyte ballooning 
and has recently been reported to reduce liver pathology in 
obese mouse models of NASH [13, 36–38]. Elafibranor is a 
high-affinity agonist for the nuclear peroxisome proliferator-
activated alpha/delta receptor (PPAR-α/δ) and ameliorates 
NASH mainly by increasing the disposal of hepatic fatty 
acid as well as inhibiting pathways involved in inflammation 
and fibrosis [13, 39, 40].
Materials and Methods
Animals
Male Wistar rats (RjHan:WI, 6 weeks of age, 200–250 g) 
were obtained from Janvier Labs (Le Genest-Saint-Isle, 
France) and housed pairwise in a controlled environment 
(21 °C ± 2 °C, humidity 50% ± 10%) with a 12-h light/
dark cycle. After acclimatizing, animals were fed either 
a choline-supplemented l-amino acid-defined (CSAA; 
E15668-04, kcal  %; protein 12%, fat 16%, carbohy-
drates 72%) control diet or a choline-deficient l-amino 
acid-defined (CDAA, kcal %; protein 11%, fat 31%, car-
bohydrates 58%) diet without cholesterol (E15667-94), 
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or supplemented with 1% cholesterol (CDAA + 1%chol, 
E15666-94) or 2% cholesterol (CDAA + 2%chol, E15665-
94) for 4, 8, or 12 weeks. CDAA diets were all low in 
methionine (0.17%) compared to the CSAA diet (0.4%). 
All diets were obtained from ssniff Spezialdiäten GmbH 
(Soest, Germany).
In a subsequent study, the effect of pharmacological 
intervention was evaluated in rats fed either CSAA or 
CDAA + 1%chol for 9 weeks followed by 5 weeks of com-
pound treatment. Three weeks prior to treatment start, a 
liver biopsy was collected for treatment stratification and 
within-subject analysis of treatment responses (see below), 
whereupon animals were single-housed during the remain-
der of the study. All animals had ad libitum access to the 
respective diets and tap water throughout the study. The ani-
mal studies were conducted according to licenses 13-011-G 
(Boehringer-Ingelheim) and 2013-15-2934-00784 (Gubra) 
and conformed with national guidelines for animal welfare.
Liver Biopsy Prior to Drug Treatment
A liver biopsy was collected according to procedures pre-
viously reported for mice [10, 11] with few modifications. 
In brief, rats were anesthetized with 3–5% isoflurane (Vet-
flurane, Virbac, Kolding, Denmark) in atmospheric air. A 
midline abdominal incision was made to expose the left 
lateral lobe, and a cone-shaped biopsy of 50–100 mg was 
collected and fixed in 4% paraformaldehyde overnight at 
room temperature for subsequent histological assessment. 
The cut surfaces were electrocoagulated using an electro-
surgical unit (VIO 100C, Erbe, Marietta, GA). The liver was 
returned to the abdominal cavity, and the abdominal wall 
and the skin were sutured. Post-operative pain and infec-
tion were controlled by administering carprofen (5 mg/kg, 
Norodyl, ScanVet, Fredensborg, Denmark) and enrofloxacin 
(5 mg/kg, Baytril, Bayer, Leverkusen, Germany) prior to 
the surgery and on post-operative days 1 and 2. Animals 
were allowed to recover for 3 weeks post-surgery before 
treatment start.
Compound Treatment
Animals were stratified to treatment (n = 12 per group) based 
on baseline mean liver collagen 1a1 (Col1a1) and lipid con-
tent (steatosis), see histological procedures below. OCA 
(Angene Chemical, London, UK) and elafibranor (Synnova-
tor Inc., Durham, NC) were dissolved in 0.5% Natrosol with 
0.01% Tween 80 and administered in a dosing volume of 
5 mL/kg. While maintained on the respective diet, animals 
received per oral (PO) dosing of vehicle, OCA (30 mg/kg/
day) or elafibranor (30 mg/kg/day) twice daily for 5 weeks. 
CSAA and CDAA control group conditions, and data have 
been described in detail previously [41].
Tissue Collection
Upon completion, animals were killed by cardiac puncture 
under pentobarbital (Narcoren, Merial GmbH, Germany) or 
isoflurane (Vetflurane, Virbac, Kolding, Denmark) anesthe-
sia, whereupon blood and liver were sampled. The blood 
sample was centrifuged (2000 g, 10 min, 4 °C), and plasma 
was collected and stored at − 80 °C. The liver was snap fro-
zen in liquid nitrogen and stored at − 80 °C until process-
ing for biochemistry triglycerides (TG) and hydroxyproline 
(HP), see below), or fixated in 4% paraformaldehyde and 
paraffin-embedded for subsequent histology (see below).
Plasma and Liver Biochemistry
Plasma levels of alanine aminotranferase (ALT) were deter-
mined using a Cobas Integra 400 or Cobas C-111 (Roche 
Diagnostics, Germany), according to the manufacturer’s 
instructions. Liver samples were homogenized using Fast-
Prep tubes in 1 mL isopropanol. Samples were centrifuged 
(18,000 g, 5 min, 4 °C), and total TG levels were deter-
mined on a Cobas Integra 400 or Cobas C-111 analyzer 
(Roche Diagnostics, Mannheim, Germany), according to 
the manufacturer’s instructions. Liver HP content was deter-
mined according to previously reported procedures [10] 
with slight modifications. In brief, samples were hydrolyzed 
in 6 M HCl at 95 °C overnight, whereupon the samples 
were brought to room temperature, mixed, and centrifuged 
at 18,000 g for 10 min at 4 °C. The supernatant was trans-
ferred to a microtube and mixed in a 96- or 384-well micro-
plate with assay and detection buffer, incubated at 65 °C, 
and measured at  A560 nm using a spectrophotometer. Liver 
HP concentrations were extrapolated from the standard 
curve.
Histology
A fresh piece of liver was sectioned and fixed in 4% para-
formaldehyde, embedded in paraffin, cut into 3–4-µm sec-
tions. Sections were subsequently stained for analysis of 
steatosis, inflammation and ballooning (hematoxylin–eosin, 
HE), fibrosis [Masson’s trichrome, Picro-Sirius red, collagen 
1a1 (Col1a1)], α-SMA, as described previously [13, 41]. 
Immunohistochemical detection of CD45-positive leuko-
cytes was performed on a Leica Bond-III autostainer (Leica 
Biosystems, Melbourne, Australia) using a polyclonal rab-
bit anti-human CD45 antibody (1:400; ab10558, Abcam) 
after heat-induced epitope retrieval with Bond™ Epitope 
Retrieval Solution 1 (ER1, Leica Biosystems, Newcastle, 
UK) for 30 min. Bound antibodies were visualized using 
the Bond™ Polymer Refine Detection System (Leica Bio-
systems, Newcastle, UK). Following scanning with the 
Axio Scan.Z1 (200 × magnification, Carl Zeiss Microscopy 
1241Digestive Diseases and Sciences (2019) 64:1238–1256 
1 3
GmbH, Jena, Germany), the CD45-positive stained area 
was determined using HALO™ (Indica Labs, Corrales, 
NM, USA). Histological scoring was performed on HE- and 
Picro-Sirius Red-stained sections by a trained histopatholo-
gist. The NAFLD activity score (NAS) and fibrosis staging 
system were applied to liver pre-biopsies and terminal sam-
ples, according to Kleiner et al. [42]. Quantitative data were 
expressed as percent staining area relative to whole sectional 
area (fractional area; HE, α-SMA, collagen, CD45), whole 
liver content (multiplication of fractional area with corre-
sponding total liver weight; HE, Col1a1), and number of 
immunopositive cells (cells per  mm2; CD45). All histologi-
cal assessments were performed by a pathologist blind to 
treatment.
RNA Isolation and Quantification
As previously described [41], liver samples (50 mg) were 
homogenized (3000 × g 3 min, Precellys Evolution, Bertin 
Technologies S.A.S, Montigny Le Bretonneux, France) 
in Lysing Matrix D Tubes (MP Biomedicals, Eschwege, 
Germany) containing RNeasy lysis buffer (Qiagen, Hilden, 
Germany) with 1% 2-mercaptoethanol added. The superna-
tant was collected, and phenol–chloroform isoamyl alcohol 
was added. Tubes were mixed and centrifuged at 12,000 × g 
for 5 min, and chloroform isoamyl alcohol was added and 
incubated for 3 min at room temperature. After a second 
centrifugation step, the upper phase was used for RNA 
extraction. Total RNA was isolated according to the man-
ufacturer’s protocol (RNeasy, Qiagen, Hilden, Germany). 
RNA concentrations (260 nm) and purity (260/280 nm 
ratio) were analyzed using a NanoDrop ND-1000 UV–Vis 
Spectrophotometer (Thermo Scientific, Karlsruhe, Ger-
many), and samples were then stored at − 80 °C until fur-
ther analysis. RNA was reverse transcribed into cDNA 
(High-capacity cDNA Archive Kit, Applied Biosystems, 
Foster city, CA). PCR amplification was carried out on a 
thermal cycler, and the cDNA was stored at − 20 °C. For 
real-time qPCR analysis, sample reactions were carried out 
in triplicate with specific primers (Itgam Rn00709342_
m1, Emr1 Rn01527631_m1, Tnfa Rn01525859_g1, 
Col1a1 Rn01463848_m1, Acta2 Rn01759928_g1, 
Tgfb Rn00572010_m1, Pai1 Rn01481341_m1, Ctgf 
Rn00573960_g1, Ehhadh Rn00592368_m1, Acox1 
Rn01460628_m1 from Applied Biosystems) and mRNA 
data were evaluated with the software provided with the 
instrument (SDS v.2.2, Applied Biosystems). mRNA lev-
els were calculated with reference to  Ct-values of a dilu-
tion series of a standard total RNA sample and normal-
ized to corresponding 18S rRNA levels. mRNA data were 
expressed as fold change to CSAA dieting for 4 weeks. For 
the drug treatment study, all mRNA data were expressed as 
fold change relative to control levels.
Statistical Analysis
All data were analyzed using either GraphPad Prism or 
RStudio software. All results are shown as mean ± standard 
error of mean (SEM). For the comparative study on different 
CDAA diet compositions, time-course data were analyzed 
using a two-way ANOVA with Tukey’s post hoc test. Treat-
ment effects were analyzed using either one-way ANOVA 
with Tukey’s post hoc test or Fisher’s exact test with Bonfer-
roni’s post hoc analysis (pre-post-analysis of fibrosis stage 
and NAS).
Results
Characterization of a Cholesterol‑Supplemented 
CDAA Rat Model of NASH
Body Weight, Liver Weight, and Plasma/Liver Biochemistry
Rats fed a CDAA diet with or without cholesterol supple-
mentation showed an initial slower body weight gain as com-
pared to CSAA-fed controls (Fig. 1a). At 12 weeks of diet-
ing, no significant weight difference was observed between 
the CSAA, CDAA, and CDAA + 1%chol groups, whereas 
rats fed CDAA + 2%chol exhibited a slight, however, nonsig-
nificant, reduction in body weight gain compared to CSAA 
controls (Fig. 1a). CDAA rats showed significantly increased 
liver weight compared to the CSAA rats with hepatomegaly 
being even more robust in rats fed cholesterol-supplemented 
CDAA diets (Fig. 1b). All CDAA-fed groups had markedly 
elevated liver TG levels irrespectively of cholesterol sup-
plementation which became less pronounced with increased 
duration of the dieting period (Fig. 1c). Similar dynamics 
were also noted for plasma ALT levels (Fig. 1d). While liver 
HP content progressively increased in CDAA-fed rats attain-
ing statistical significance in dieting week 8 and 12, dietary 
cholesterol supplementation to the CDAA diet did not fur-
ther influence liver HP levels (Fig. 1e).
Histology and Gene Expression Analyses
Representative images of liver HE, Masson’s trichrome, 
and α-SMA staining following 12 weeks of dieting are 
shown in Fig. 2. In general, the CDAA diet regimen led 
to marked alterations in liver pathology as evident by 
increased steatosis (primarily as macrovesicular steatosis), 
with inflammatory changes and increased fibrosis. Fibrosis 
consisted of fibers forming periportal–periportal, peripor-
tal–centrolobular, or centrolobular–centrolobular bridges 
with frequent nodule formations. Periportal inflammation 
and ballooning degeneration were observed, indicative 
of a progression from simple steatosis to steatohepatitis. 
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Histopathological scores indicated onset of marked stea-
tosis and mild-to-moderate lobular inflammation after 
4 weeks of CDAA dieting irrespectively of cholesterol 
supplementation (Fig. 3a, b). Whereas steatosis sever-
ity tended to be reduced with prolonged CDAA dieting, 
inflammation scores were further elevated following 
12 weeks of CDAA dieting. Hepatocyte ballooning was 
only consistently detected after 12 weeks of CDAA diet-
ing (Fig. 3c).
As compared to CSAA controls, quantitative liver 
lipid deposition was markedly increased in all individual 
CDAA dieting periods. The steatosis-inducing effect of the 
CDAA diet was unaffected by cholesterol supplementation 
(Fig. 4a). As for steatosis scores, the effect of CDAA dieting 
B
A
C
D E
Fig. 1  Metabolic parameters during NASH progression. a Weekly 
body weight throughout the diet induction. b Liver weight at termina-
tion. c Liver TG content at termination. d Plasma alanine aminotrans-
ferase (ALT) at termination. e Liver HP content at termination. 
#P < 0.05 versus CSAA, *P < 0.05 versus CDAA, ∆P < 0.05 versus 
same diet at 4 weeks, $P < 0.05 versus same diet at 8 weeks
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on quantitative liver lipid deposition was gradually reduced 
with increased dieting periods and, however, remained sig-
nificantly elevated throughout the experiment (~ 30% fat) as 
compared to CSAA controls (~ 0.7% fat). Hepatic α-SMA 
levels (marker of activated hepatic stellate cells) were mark-
edly upregulated in CDAA rats after 4 weeks dieting and 
remained stable at 8 and 12 weeks of dieting (Fig. 4b). Cho-
lesterol supplementation did not stimulate α-SMA expres-
sion as compared to CDAA dieting alone. Liver collagen 
levels (based on Masson’s trichrome analysis) were also 
increased with CDAA dieting, showing a clear temporal 
progression with the highest levels observed after 12 weeks 
of dieting (Fig. 4c). Compared to CDAA dieting alone, cho-
lesterol supplementation promoted more robust increases 
in collagen levels at dieting weeks 8 and 12. This tempo-
ral effect was closely paralleled by substantial increases 
in the expression of Col1a1 mRNA (Fig. 4d), as well as 
other transcripts associated with signaling pathways that 
stimulate fibrogenesis (Acta2, Ctgf) or inhibit fibrinolysis 
(Pai1) (see Table 1). Alterations in liver inflammation upon 
CSAA
CDAA
CDAA+
1%chol
CDAA+
2%chol
Hematoxylin-eosin α-SMAMasson’s trichrome
Fig. 2  Liver histopathology during NASH progression. Representa-
tive images of hematoxylin–eosin, Masson’s trichrome and α-SMA 
staining after 12  weeks on the respective diets. Figure inserts in 
hematoxylin–eosin photomicrographs for visualizing inflammatory 
cell infiltrates upon CDAA dieting. Scale bar, 100 µm
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CDAA dieting were further suggested by markedly elevated 
levels of CD45-immunostained fractional area, numbers of 
CD45-immunopositive cells (Fig. 5), as well as mRNA lev-
els of Itgam (implicated in leukocyte adhesive interactions), 
Emr1 (T cell regulatory protein), and Tnfα (inflammatory 
cytokine) (see Table 1). Cholesterol supplementation to 
the CDAA diet promoted further increments in the expres-
sion of these genes, being particularly evident for Itgam 
and Tnfa.  
Drug Treatment in Rats Fed 
Cholesterol‑Supplemented CDAA Diet
The effects of OCA and elafibranor treatment were evalu-
ated in rats fed CDAA + 1%chol diet. All animals underwent 
liver biopsy 3 weeks before dosing start. Randomization 
and stratification to treatment were performed based on a 
quantitative histological assessment of individual baseline 
levels of liver Col1a1 and lipid deposition (fractional area). 
Vehicle-dosed CSAA and CDAA + 1%chol controls exhib-
ited similar growth curves (Fig. 6a). When expressed relative 
to baseline, CDAA + 1%chol controls exhibited a slightly 
higher body weight gain compared to CSAA controls 
(Fig. 6b). Treatment with OCA (30 mg/kg/day) and elafi-
branor (30 mg/kg/day) did not affect absolute body weight 
in CDAA + 1%chol fed rats (Fig. 6a). When expressed as 
body weight gain relative to treatment start, OCA treatment 
marginally reduced the rate of body weight gain from treat-
ment day 26 and onwards (Fig. 6b). In contrast, elafibranor 
treatment initially led to a modest increase in body weight 
gain, which gradually wore off during the remainder of the 
treatment period (Fig. 6b).
At study termination, CDAA + 1%chol fed rats had 
a significantly increased liver weight and TG content, as 
compared to CSAA controls (Fig.  6c, d). Plasma ALT 
levels were similar in CSAA and CDAA + 1%chol rats 
(Fig. 6e), whereas liver HP levels were markedly elevated in 
CDAA + 1%chol rats (Fig. 6f). While OCA treatment had no 
effect on hepatomegaly in CDAA + 1%chol rats, elafibranor 
treatment resulted in a marked increase in liver weight com-
pared to CSAA controls (Fig. 6c), accompanied by increased 
mRNA expression of the peroxisomal enzymes, Acox1 and 
Fig. 3  Histopathological scores 
during NASH progression. a 
Steatosis, b inflammation, c 
hepatocyte ballooning degen-
eration
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Ehhadhm (Table 2). OCA and elafibranor did not affect liver 
TG and plasma ALT levels in CDAA + 1%chol rats (Fig. 6d, 
e). In contrast, elafibranor, but not OCA, resulted in a sig-
nificant reduction in liver HP levels (Fig. 6f).
A comparative analysis of pre-biopsy (from dieting week 
6) and terminal hepatopathology (dieting week 14) was per-
formed in all rats (Fig. 7). Baseline hepatic steatosis (score 
3) and lobular inflammation (score ≥ 2) were prominent 
histopathological features in CDAA + 1%chol rats. When 
present, ballooning was mild in CDAA + 1%chol rats (score 
1). CSAA rats generally showed normal liver histopathology 
and remained nonfibrotic (score 0, 12/12). As compared to 
baseline, the temporal dynamics in NASH were not uniform 
in CDAA + 1%chol control rats (NAS, lower 6/12, same 
4/12, higher 2/12, Fig. 7b). While pre-post steatosis scores 
remained unchanged in all CDAA + 1%chol rats (Fig. 7c), 
a subset of vehicle-dosed CDAA + 1%chol rats showed 
reduced inflammation (5/12 rats, Fig. 7d) and ballooning 
scores (4/12 rats, Fig. 7e) at termination compared to base-
line. Compared to CDAA + 1%chol controls, OCA treat-
ment did not influence NAS (lower 6/11, same 3/11, higher 
2/11). In contrast, elafibranor significantly improved NAS 
(lower 12/12, P < 0.05) in CDAA + 1%chol rats (Fig. 7a, 
b). Improved NAS in elafibranor-treated CDAA + 1%chol 
rats was driven by consistent reductions in steatosis scores 
(11/12 rats, P < 0.001, Fig. 7a, c), and to a lesser extent, by 
resolution of ballooning scores (9/12 rats, P > 0.05, Fig. 7e). 
Compared to vehicle CDAA + 1%chol controls, inflamma-
tion scores were not significantly changed in elafibranor-
treated CDAA + 1%chol rats (Fig. 7d). However, transcrip-
tional levels of inflammation markers (Itgam, Emr1, Tnfα, 
Tgfβ) were significantly reduced following elafibranor treat-
ment (Table 2).
Fibrosis staging indicated that almost all vehicle-
dosed CDAA + 1%chol rats (11/12) progressed in fibrosis 
severity over the course of the experiment (Fig. 8). Most 
CDAA + 1%chol controls exhibited severe liver fibrosis 
morphology (score 0, 1/12; score 1, 3/12; score 3, 3/12 rats; 
score 4, 5/12 rats), i.e., bridging fibrosis or cirrhosis histo-
pathology was predominant at study termination (Fig. 8a, c). 
Irrespective of treatment, fibrosis stage 2 (combined perisi-
nusoidal and portal/periportal fibrosis) was not observed in 
rats fed CDAA + 1%chol diet (n = 33). CSAA control rats 
remained nonfibrotic (score 0, 12/12). Fibrosis scores were 
not significantly altered upon OCA (lower 0/11, same 3/11, 
higher 8/11) and elafibranor (lower 1/12, same 5/12, higher 
A B
C D
Fig. 4  Histomorphometric changes during NASH progression. Fractional area of a steatosis, b α-SMA, c collagen. d Col1a1 mRNA expression. 
#P < 0.05 versus CSAA, *P < 0.05 versus CDAA. ∆P < 0.05 versus same diet at 4 weeks, $P < 0.05 versus same diet at 8 weeks
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6/12) treatment, as compared to vehicle controls (lower 0/12, 
same 3/12, higher 9/12).
Quantitative liver fat analysis indicated that elafibranor, 
but not OCA, significantly reduced the fractional area of 
fat in CDAA + 1%chol rats (Fig. 9a, P < 0.001). In contrast, 
elafibranor had no significant effect on liver fat deposition 
when expressed as whole liver content (Fig. 9b, P > 0.05). 
The fractional area of Col1a1 was similar in vehicle and 
OCA-dosed CDAA + 1%chol rats and, however, tended to 
be reduced with elafibranor treatment (Fig. 9c). No changes 
were observed when expressed as total liver Col1a1 content 
(Fig. 9d). Elafibranor, but not OCA, significantly reduced 
Col1a1 mRNA levels (Table 2).
Discussion
The present study characterized the impact of cholesterol 
supplementation in a CDAA diet-induced rat model of 
NASH. In agreement with previous studies [22, 23, 43], the 
standard CDAA diet was weight neutral in Wistar rats over 
a 12-week dieting period compared to rats receiving the 
CSAA control diet. Hepatomegaly, hepatic steatosis, and TG 
accumulation were prominent in rats fed the standard CDAA 
diet. Dietary cholesterol supplementation did not affect 
body weight gain, but accentuated hepatomegaly in CDAA 
diet-fed rats. Choline-deficient diets, including CDAA, are 
highly lipotrope and considered to promote steatosis as a 
result of increased fatty acid uptake and impaired hepatic TG 
secretory capacity [20, 44–46]. Similarly, increased dietary 
cholesterol intake is suggested to aggravate high-fat diet-
induced steatosis by comparable mechanisms [13, 47, 48]. 
However, cholesterol supplementation did not lead to corre-
sponding increases in hepatic TG deposition and steatosis in 
the present study, potentially due to a maximal suppression 
of hepatic TG secretion afforded by the CDAA diet alone. 
As choline deficiency has been reported to reduce biliary 
cholesterol excretion in rats [49], enhanced hepatomegaly 
may therefore tentatively be explained by hepatic choles-
terol accumulation per se. Irrespective of cholesterol sup-
plementation, liver TG levels and steatosis severity peaked 
early in the CDAA dieting period and became less prominent 
over time. In contrast, hepatic HP content, Col1a1 levels, 
and fibrogenic activity increased during the diet induction 
period. Similar opposing dynamics in liver TG and colla-
gen deposition have also been reported in Fischer rats and 
C57BL/6J mice fed a standard CDAA diet for 12–14 weeks 
[20, 50].
It is well established that hepatocyte integrity is increas-
ingly affected when NASH advances [51, 52]. This is also 
evident in CDAA diet-fed rats that show morphological 
features of hepatocellular damage, apoptosis (cell shrink-
age/condensed nuclei), and connective tissue formation 
already after 4 weeks of dieting [53]. In rats fed the vari-
ous CDAA diet types, hepatic inflammatory activity was 
suggested by significantly upregulated gene expression of 
Itgam, Emr1, and Tnfα, being in agreement with previous 
reports on recruitment of various immune cell populations 
[54–57] and increased hepatic TNF-α levels [58, 59] in other 
rodent CDAA diet-based models of NASH. The progres-
sive increase in CD45-positive cells closely paralleled cor-
responding inflammation scores, indicating that leukocyte-
mediated inflammation plays an integral role in development 
of the NASH phenotype of CDAA diet-fed rats. Although 
the specific composition of immune cell infiltrates was not 
characterized in the present study, activated liver-resident 
Kupffer cells and recruitment of extrahepatic macrophages 
have been suggested to play an important role in the initia-
tion and progression of CDAA diet-induced liver inflam-
mation [58–60], being consistent with the finding that the 
hepatic macrophage pool undergoes substantial changes dur-
ing development of NASH [61–63].
Interestingly, the cholesterol-supplemented CDAA diet 
promoted more robust increases in Col1a1 expression, par-
ticularly at the mRNA level, and further stimulated mRNA 
expression of Itgam, Emr1, and Tnfα. The cholesterol-sup-
plemented CDAA diet formulations tested in the present 
study were equally effective in promoting fibrotic NASH 
in rats. Collectively, these findings extend data recently 
reported by our research group [41] and suggest that cho-
lesterol supplementation enhances the lipotrope properties 
of the CDAA diet, thereby further compromising liver func-
tion in the rat.
To further characterize the modified CDAA diet-induced 
rat model of NASH, a comparative pharmacological study 
was performed to determine effects of OCA and elafibranor 
treatment in rats fed a CDAA diet added 1% cholesterol. 
Because disease state heterogeneity is a critical confounding 
factor in the evaluation of treatment efficacy in both human 
NASH and animal models of the disease [9, 64], a baseline 
liver biopsy was sampled to enable within-subject analysis 
of treatment responses upon study termination. Moreover, 
the diagnostic liver pre-biopsy allowed for stratification of 
individual treatments based on baseline liver Col1a1 and 
fat deposition. Morphometric and quantitative histologi-
cal analyses confirmed that rats rapidly developed NASH 
when fed a cholesterol-supplemented CDAA diet. The 
human NAFLD activity scoring (NAS) system is previously 
reported largely reproducible in rodent models of NASH 
Fig. 5  Leukocyte infiltration during NASH progression. a Represent-
ative images of CD45-positive leukocyte staining after 4–12  weeks 
on the respective diets. b Quantitative analysis of CD45-positive frac-
tional area. c Quantitative analysis of the number of CD45-positive 
cells. Scale bar, 50  µm. #P < 0.05 versus CSAA, ∆P < 0.05 versus 
same diet at 4 weeks, $P < 0.05 versus same diet at 8 weeks
◂
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[65], including standard CDAA diet-induced models [43, 
66], and was therefore applied in the present study.
Rats fed a cholesterol-enriched CDAA diet for 6 weeks, 
i.e., 3 weeks prior to treatment start, fulfilled morphologi-
cal criteria of NASH by the conspicuous presence of severe 
steatosis (score 3), moderate to marked lobular inflammation 
(score 2–3), and mild ballooning (score 1). Within-subject 
analysis in vehicle controls indicated sustained steatosis 
scores upon completion of dosing (14 weeks on diet), how-
ever, with a net reduction in inflammation and ballooning 
scores. These histopathological scoring data indicate spon-
taneous regression of inflammation and hepatocyte balloon-
ing in a subset of rats fed the modified CDAA diet. Similar 
dynamics have previously been reported in mice fed a high-
fat CDAA diet without cholesterol supplementation [20]. 
Most rats fed the cholesterol-supplemented CDAA diet were 
mildly fibrotic at baseline, and fibrosis progression was evi-
dent by markedly elevated fibrosis scores at study termina-
tion. Irrespectively of treatment, a subset of rats remained 
nonfibrotic or did not progress in fibrosis stage over the 
course of the study. These findings are in close agreement 
with previous reports on marked individual differences in the 
rate of NASH progression in rats fed a standard CDAA diet 
[41, 43], which argues for the importance of controlling for 
individual disease progression in CDAA diet-based models 
of NASH.
Drug treatment had very modest effects on body weight 
in rats fed the modified CDAA diet. Elafibranor, but not 
OCA, further increased liver weight without affecting 
hepatic TG deposition. A similar effect of elafibranor has 
been reported in diet-induced obese mouse models of 
NASH [13, 67], considered to be a rodent-specific PPAR-α 
stimulatory effect on hepatocyte peroxisome proliferation 
[68–70]. Elafibranor treatment led to a consistent reduc-
tion in NAS, predominantly associated with significantly 
reduced steatosis scores. This observation was also sup-
ported by a lower percentage of liver fat content. However, 
when corrected for the higher liver mass no changes in 
total liver fat content were observed in elafibranor-treated 
rats compared to vehicle controls. Likewise, total liver TG 
content remained unchanged, signifying that elafibranor 
treatment altered liver fat morphology but had no overall 
effect on liver fat content. Although liver HP content was 
significantly reduced, fibrosis scores were unaltered after 
5 weeks of elafibranor treatment. Whereas liver Col1a1 
protein levels were not sufficiently reduced to attain statis-
tical significance, Col1a1 gene transcription was signifi-
cantly downregulated and corresponding Col1a1 protein 
expression remained low, albeit this effect did not attain 
statistical significance. In combination with the reduction 
in transcriptional markers associated with inflammation 
and stellate cell activation, this indicates that several dis-
ease-associated gene expression programs were markedly 
suppressed by elafibranor treatment. The lack of improved 
histopathology in the context of notable reductions in 
transcriptional markers of inflammation and fibrogenesis 
invites the possibility that prolonged treatment with elafi-
branor might lead to reduced inflammatory and fibrotic 
pathology in the present rat model of NASH, thereby more 
closely recapitulating clinical effects of elafibranor [31]. 
Accordingly, a similar dose of elafibranor has previously 
been shown to reduce steatohepatitis and liver fibrosis fol-
lowing 7 weeks of treatment to MCD diet-fed db/db mice 
[67], and other PPAR agonists can reduce fibrotic NASH 
Fig. 6  Metabolic parameters following drug treatment. a Daily 
body weight. b Body weight relative to day 0. c Liver weight. d 
Liver TG. e Plasma alanine aminotransferase (ALT). f Liver HP. 
#P < 0.05, ##P < 0.01, ###P < 0.001 versus CSAA vehicle, **P < 0.01, 
***P < 0.001 versus CDAA + 1%chol vehicle
◂ Table 2  mRNA expression of Acox1, Ehhadh, Itgam, Emr1, Tnfα, 
Tgfβ, Col1a1, and Acta2 from drug treatment study
## P < 0.01, ###P < 0.001 versus CSAA vehicle, *P < 0.05, **P < 0.01, 
***P < 0.001 versus CDAA + 1%chol vehicle
Gene CSAA Vehicle OCA Elafibranor
Acox1 1.0 ± 0.3 0.6 ± 0.0 0.6 ± 0.0 4.4 ± 0.7***
Ehhadh 1.0 ± 0.3 1.0 ± 0.1 0.9 ± 0.1 21.9 ± 1.9***
Itgam 1.0 ± 0.1## 12.8 ± 3.4 14.9 ± 2.4 4.0 ± 0.6*
Emr1 1.0 ± 0.2## 1.8 ± 0.2 2.0 ± 0.2 0.9 ± 0.0**
Tnfα 1.0 ± 0.2### 5.3 ± 0.6 6.7 ± 1.0 2.3 ± 0.3**
Tgfβ 1.0 ± 0.1### 4.7 ± 0.5 5.1 ± 0.7 2.0 ± 0.1***
Col1a1 1.0 ± 0.2## 21.3 ± 4.3 28.0 ± 6.7 6.0 ± 1.0*
Acta2 1.0 ± 0.3 2.2 ± 0.3 2.8 ± 0.5 0.9 ± 0.2
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when administered for 10–12  weeks in mouse and rat 
CDAA models [23, 71]. Previous studies have reported 
anti-steatotic, anti-inflammatory, and anti-fibrotic effects 
of PPAR subtype-selective agonists for the α [72, 73], δ 
[74, 75], and γ [76, 77] isoforms, making it conceivable 
that elafibranor, a dual PPAR-α/δ agonist, exerts its thera-
peutic effects through various PPAR-associated signaling 
mechanisms.
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Fig. 7  NASH pathology after drug treatment. a Representative images of hematoxylin–eosin stainings. b Composite NAFLD Activity Score 
(NAS). c Steatosis score. d Inflammation score. e Ballooning degeneration score. *P < 0.05, ***P < 0.001 versus CDAA + 1%chol vehicle
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OCA did not affect hepatopathology in Wistar rats fed 
a modified CDAA diet, which contrasts a recent clinical 
phase-II trial, reporting significant improvements in all 
NAS components following OCA treatment [30]. A previ-
ous study reported that OCA significantly lowered hepatic 
collagen deposition, in a CDAA model in Fischer rats [24], 
possibly suggesting strain-dependent effects of OCA in the 
rat CDAA model of NASH, whereas another FXR agonist, 
WAY-362450, had no effect on steatosis, however reduced 
hepatic inflammatory cell infiltration, pro-fibrotic gene 
expression and collagen deposition in MCD diet-fed mice 
[78]. Both studies administered FXR agonists during the 
whole dieting period (i.e., before onset of NASH), implying 
that this drug class may only prevent, and not reverse, liver 
fibrosis in nutrient-deficient diet-induced models of NASH.
In conclusion, we have characterized a novel choles-
terol-supplemented CDAA rat model of NASH with robust 
hepatic fibrosis. Biopsy-confirmed histopathology was 
applied to control for individual rates of disease progression, 
which provided a unique opportunity to study within-subject 
treatment responses in the model. The model reflects the 
human NASH phenotype and disease progression, and due 
to the stable induction of the phenotype within a short time 
frame, this model could serve as a valuable tool to character-
ize novel treatments in NASH.
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